Transcatheter treatment option addresses an unmet need
“Today, TAVI allows patients who are at very high surgical risk or with contraindications to surgical AVR to benefit from an effective treatment of AS.”
–D. Himbert, Bichat Hospital, Paris1
Transcatheter aortic valve implantation
A new option for patients with severe AS considered to be high risk for surgical AVR is transcatheter aortic valve implantation, or TAVI. In this procedure, the valve is delivered via transfemoral, transapical or transaortic access without open-heart surgery. The Edwards SAPIEN valve received the CE mark in 2007.
- Himbert D, Descoutures F, Al-Attar N, et al. Results of transfemoral or transapical aortic valve implantation following a uniform assessment in high-risk patients with aortic stenosis. J Am Coll Cardiol 2009; 54:303-11.
Any quotes used in this material are taken from independent third-party publications and are not intended to imply that such third party reviewed or endorsed any of the products of Edwards Lifesciences.